F-1/A: TNL Mediagene Files for Resale of Ordinary Shares and Warrants After Merger

TNL Mediagene registers for the resale of ordinary shares and warrants by selling securityholders following its merger with Blue Ocean Acquisition Corp.

Summary

• TNL Mediagene has filed a registration statement for the resale of up to 11,832,277 ordinary shares and 2,908,047 warrants.
• The selling securityholders include 3i, Tumim Stone Capital LLC, Existing PIPE Convertible Note Investors, DaEX Conversion Right Holders, and November PIPE Convertible Note Investors.
• The registration covers ordinary shares issued from convertible notes, conversion rights, and warrants.
• The company will not receive any proceeds from the resale of these securities by the selling securityholders, except upon exercise of the warrants.
• TNL Mediagene completed its merger with Blue Ocean Acquisition Corp on December 5, 2024.
• The company is also registering the offer and resale of up to 2,200,000 TNL Mediagene Warrants and up to 2,200,000 TNL Mediagene Ordinary Shares issuable upon exercises of up to 2,200,000 TNL Mediagene Warrants by Mediagene Inc., its subsidiary, or its permitted transferees.

Sentiment

Score: 4

Explanation: The document is primarily a legal filing, so the sentiment is neutral. However, the fact that the stock price is significantly below the warrant exercise price and that the company has a history of losses suggests a slightly negative outlook.

Positives

• The registration statement allows selling securityholders to freely sell their securities in the public market.
• TNL Mediagene completed its merger with Blue Ocean Acquisition Corp, becoming a publicly listed company.

Negatives

• TNL Mediagene will not receive any proceeds from the resale of ordinary shares and warrants by the selling securityholders, except upon exercise of the warrants.
• The exercise price of the warrants is $11.50, while the current trading price is significantly lower at $2.47, making it unlikely that warrant holders will exercise their warrants.

Risks

• The market price of TNL Mediagene's securities may be volatile and could decline.
• Sales of a substantial number of shares in the public market could cause the price of TNL Mediagene Ordinary Shares and TNL Mediagene Warrants to fall.
• The company may redeem unexpired warrants prior to their exercise at a time that is disadvantageous to warrant holders.
• The company may not meet the expectations of equity research analysts, which could cause the price of its securities to decline.
• The company's issuance of additional share capital will dilute all other shareholders.
• The company does not intend to pay dividends for the foreseeable future.
• The company has identified material weaknesses in its internal control over financial reporting.

Future Outlook

The company may receive up to $30.0 million in gross proceeds from sales of TNL Mediagene Ordinary Shares to Tumim under the Tumim ELOC SPA from time to time after the date of this prospectus.

Industry Context

The announcement reflects a common practice among SPAC mergers, where early investors seek to monetize their holdings after the lock-up periods expire. The success of the resale depends on market conditions and investor sentiment towards TNL Mediagene.

Comparison to Industry Standards

• It is difficult to compare TNL Mediagene to industry standards without specific financial data included in the document.
• However, the document does mention that TNL Mediagene Ordinary Shares are quoted on The Nasdaq Capital Market (Nasdaq) under the symbol TNMG.
• On February 6, 2025, the last reported trading date for TNL Mediagene Ordinary Shares, the closing price of TNL Mediagene Ordinary Shares was $2.47 per share.

Stakeholder Impact

• Existing shareholders may experience dilution if warrants are exercised or if additional shares are issued to Tumim.
• The market price of TNL Mediagene Ordinary Shares and TNL Mediagene Warrants could be depressed by sales of a substantial number of shares in the public market by the existing securityholders.

Next Steps

• The selling securityholders will determine when and how they will dispose of the securities being registered for resale.
• TNL Mediagene may receive up to $30.0 million in gross proceeds from sales of TNL Mediagene Ordinary Shares to Tumim under the Tumim ELOC SPA from time to time after the date of this prospectus.

Key Dates

Keywords

TNL Mediagene, Blue Ocean Acquisition Corp, resale, ordinary shares, warrants, selling securityholders, merger, registration statement, PIPE, convertible notes